Exhibit 99-1

CONTACT:

Jane Pritchett Henderson

Chief Financial and Business Officer

617-926-1551

Panacos Reports Second Quarter 2008 Financial Results

Watertown, MA (July 30, 2008)

– Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced its financial results for the second quarter of 2008 and reviewed progress in its development programs.

“We continue to make significant progress in bevirimat’s development program. We have identified the target patient population, and we are moving forward with confidence,” said Alan W. Dunton, MD, President and Chief Executive Officer of Panacos. “Using a simple and rapid genotype assay, we are able to identify the HIV patients prior to initiating treatment who should respond well and are the best candidates for bevirimat. Based on our recently announced prospective clinical study in HIV patients, we believe we have identified the ideal patient profile that will be incorporated into future clinical studies of bevirimat, including Phase 3 studies, pending regulatory concurrence. Additionally, we have created tablet formulations that we believe will allow all patients to reach the optimal plasma concentration and will be moving the formulations into the clinic. We also are actively seeking a partner for bevirimat to assist us with conducting the Phase 3 studies and to commercialize the product worldwide. Our next-generation maturation program has achieved a significant milestone as our scientists have identified several compounds that retain activity against polymorphisms in the molecular target, Gag.”

“On the corporate front, we have announced we transferred our Nasdaq listing to Nasdaq Capital Market from Nasdaq Global Market and are deferring for now any action on a reverse split, which was approved by our stockholders at our recent annual meeting. Also, we will explore partnership opportunities for our pipeline products to maximize shareholder value,” concluded Dr. Dunton.

Financial Highlights:

For the second quarter of 2008, Panacos reported a net loss of $9.7 million, or $0.18 per share, versus a net loss of $10.1 million, or $0.19 per share, for the second quarter of 2007. Revenue from research funding in the second quarter of 2008 decreased to $18,000 from $106,000 in the second quarter of 2007.

Research and development expenses in the second quarter of 2008 increased to $6.7 million from $6.2 million in the second quarter of 2007, due primarily to increased external expenditures in the Company’s research and development programs. General and administrative expenses in the second quarter of 2008 decreased to $2.6 million from $3.5 million in the second quarter of 2007.


The following information was filed by Panacos Pharmaceuticals, Inc. (PANC) on Wednesday, July 30, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Panacos Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Panacos Pharmaceuticals, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account